en · de · es · pt
compound-index.peptides6908.com › Topic › Background And Molecular Profile — Evidence Review

Background And Molecular Profile — Evidence Review

By Editorial Desk · published 2025-11-26 · last reviewed 2025-12-25 · Topic

A practical reference on thymus extract: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2025-12-25. Anything still debated is marked as such rather than presented as settled.

Background and Molecular Profile

The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.

Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.

The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.

分子身份与天然来源

市售的胸腺素α1通常以冻干粉形式提供,溶解后用于注射。其氨基酸组成包括多个酸性残基,因此在中性pH下带负电荷。该肽可溶于水和生理盐水,但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度,溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。

胸腺素α1(thymosin alpha 1,Tα1)是一种由28个氨基酸组成的酸性肽,N端被乙酰化,分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离,属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守,提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置,并非表示亚型编号。它既存在于胸腺,也存在于脾脏和淋巴结等免疫组织。

20世纪70年代,研究者从胸腺提取物中纯化出多种小肽,Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤,产量低且成分复杂。随着固相肽合成技术成熟,实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上,并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。

Thymosin-alpha-1 at a glance

PropertyValueNotes
Chemical classAcetylated peptideN-terminal acetyl group blocks aminopeptidase attack
Residue count28 amino acidsMatches the N-terminus of prothymosin alpha
Molecular massAbout 3,108 DaValue for the free, unmodified peptide
Isoelectric pointApproximately 4.2Acidic; net negative charge at neutral pH
Encoding genePTMAHuman gene for the precursor protein

Molecular Structure and Biological Background

Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.

The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.

Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.

Related pages on this site

Handling, Storage, and Analytical Verification

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.

Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.

Molecular Background and Identity

Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.

Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.

Molecular Identity Of Thymosin Alpha-1

Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.

Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.

Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.

Background from the literature

C-terminus Also carboxyl terminus. The end of a linear chain of amino acids (i.e. a peptide) that is terminated by the free carboxyl group (–COOH) of the last amino acid to be added to the chain during translation. This amino acid is said to be C-terminal. By convention, sequences, domains, active sites, or any other structure positioned nearer to the C-terminus of the polypeptide or the folded protein it forms relative to others are described as downstream. Contrast N-terminus.

The group takes its name from Mighei (Ukraine), but the most famous member is the extensively studied Murchison meteorite. Many falls of this type have been observed and CM chondrites are known to contain a rich mix of complex organic compounds such as amino-acids and purine/pyrimidine nucleobases. CM chondrite famous falls:

Each of these walkways is bordered by London plane (Platanus × hispanica) trees, which contribute to the park's European feel. In addition, numerous statues are scattered throughout the park. A raised terrace on the eastern side of the lawn, which dates to the construction of the library's main branch, is paved with gray flagstones and red brick. Its centerpiece is the William Cullen Bryant Memorial, which is raised on a pedestal of its own. A restroom structure is located at the northern border of the park along 42nd Street. A carousel, installed in 2002, is located at the park's southern border. The park is served by the New York City Subway's 7, <7>​​, B, ​D, ​F, <F>, and ​M trains at 42nd Street–Bryant Park/Fifth Avenue station, entrances to which are located on the northern and western borders of the park, as well as MTA Regional Bus Operations' M1, M2, M3, M4, M5, M7, M42, M55 and Q32 routes.

Simcere Pharmaceutical Group or Simcere Pharmaceutical (Chinese: 先声药业, SEHK: 2096) is a manufacturer and supplier of branded generic pharmaceuticals in the Chinese market. Its focus is to introduce generic and pharmaceutical products for the treatment of diseases with high incidence and/or mortality rate. The company has introduced a generic anti-stroke medication under the brand name, Bicun, and an anti-cancer medication under the brand name, Endu. Its products include antibiotics, anti-stroke medications, anti-inflammatory drugs, anti-cancer medications and other medicines. In addition, it has obtained approvals from the China State Food and Drug Administration (SFDA) to manufacture and sell over 210 other products.

== Production == Diglycerides are a minor component of many seed oils and are normally present at ~1–6%; or in the case of cottonseed oil as much as 10%. Industrial production is primarily achieved by a glycerolysis reaction between triglycerides and glycerol. The raw materials for this may be either vegetable oils or animal fats.

Sources: en.wikipedia.org

Reference notes

===== Flutamide ===== There is tentative evidence for flutamide in women; however, it is associated with relatively high rates of liver problems and strong recommendations have been made against its use. Like spironolactone, flutamide is typically only used by women. Bicalutamide is another option for the treatment of female pattern hair loss. It has a far lower risk of liver toxicity than flutamide and is said to have an excellent safety profile. However, bicalutamide retains a small risk of liver toxicity and for this reason periodic liver monitoring is recommended during treatment.

== Development == The penis derives from the genital tubercle, which develops into the phallus under the influence of androgens from the testis. Elongation draws the urethral folds forward to form the lateral walls of the urethral groove, whose epithelial lining becomes the urethral plate. The penile urethra is formed when the urethral folds enclose this plate, a process usually complete towards the end of the third month; the most distal part of the urethra forms at the end of the fourth month. Fusion of the two urethral folds gives rise to the spongy body, and two cavernous bodies arise above it to become the corpora cavernosa.

=== Breaking the C-N bond and product release === The hydroxide ion joins with the carbon atom of the creatine's amidino group, creating a tetrahedral intermediate product. This intermediate product collapses and breaks the C-N bond, releasing urea. The remainder of the molecule rearranges to form sarcosine, and both products diffuse from the active site pocket.

The three substrates of this enzyme are D-glyceraldehyde 3-phosphate, phosphate (Pi), and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are 1,3-bisphosphoglyceric acid, reduced NADPH, and a proton.

Sources: en.wikipedia.org

Reference notes

== Medical uses == Suzetrigine is indicated for the treatment of moderate to severe acute pain in adults. It was primarily studied in people with postoperative pain, including due to abdominoplasty and bunionectomy. However, a small minority of patients received suzetrigine for non-surgical pain, including arthralgias, limb pain, and sprains and strains. Treatment of acute pain using suzetrigine has not been studied beyond 14 days of use. In clinical studies conducted through 2024, suzetrigine reduced pain typically from 7 to 4 on the standard numeric scale used to rate pain. The efficacy of suzetrigine was evaluated in two randomized, double-blind, placebo- and active-controlled trials of acute surgical pain, one following abdominoplasty and the other following bunionectomy. Both trials found that suzetrigine reduced pain more effectively than placebo. Suzetrigine was not superior to placebo for the treatment of lumbosacral radiculopathy. However, in clinical studies, no superiority over hydrocodone and paracetamol (acetaminophen) in terms of pain reduction was shown over 48 hours. Medical professionals have noted its efficacy may be inferior to high-dose opioid analgesics. There are no studies comparing suzetrigine with high-dose opioids. Suzetrigine exhibits CYP3A4-mediated drug interactions and there is limited long-term data regarding its use. Moreover, usage has not been studied in those younger than 18 or older than 80 years of age and its cost-effectiveness is disputed.

== Manufacturing == It is frequently sold as a sulfate salt known as hydroxychloroquine sulfate. In the sulfate salt form, 200 mg is equal to 155 mg of the pure form. Brand names of hydroxychloroquine include Plaquenil, Hydroquin, Axemal (in India), Dolquine, Quensyl, and Quinoric.

Interventional radiology (IR or sometimes VIR for vascular and interventional radiology) is a subspecialty of radiology in which minimally invasive procedures are performed using image guidance. Some of these procedures are done for purely diagnostic purposes (e.g., angiogram), while others are done for treatment purposes (e.g., angioplasty). The basic concept behind interventional radiology is to diagnose or treat pathologies, with the most minimally invasive technique possible. Minimally invasive procedures are currently performed more than ever before. These procedures are often performed with the patient fully awake, with little or no sedation required. Interventional radiologists and interventional radiographers diagnose and treat several disorders, including peripheral vascular disease, renal artery stenosis, inferior vena cava filter placement, gastrostomy tube placements, biliary stents and hepatic interventions. Radiographic images, fluoroscopy, and ultrasound modalities are used for guidance, and the primary instruments used during the procedure are specialized needles and catheters. The images provide maps that allow the clinician to guide these instruments through the body to the areas containing disease. By minimizing the physical trauma to the patient, peripheral interventions can reduce infection rates and recovery times, as well as hospital stays. To be a trained interventionalist in the United States, an individual completes a five-year residency in radiology and a one- or two-year fellowship in IR.

All corneal grafts are screened for the presence of viruses such as HIV or hepatitis through antibody or nucleic acid testing, and there has never been a reported case of HIV transmission through corneal transplant surgery. Prior to the development of reliable HIV testing, many countries instituted bans on corneal donation by gay men. For example, on 20 May 1994, the United States banned corneal donation by any man who has had sex with another man in the preceding 5 years, even if all HIV testing is negative (a policy which continues to be enforced today).

Over the years, multiple synthesizers have been developed to assist with automated synthesis, including the Chemspeed Accelerator (SLT106, SLT II, ASW2000, SwingSLT, Autoplant A100, and SLT100), the Symyx system, and Freeslate ScPPR. Recently, researchers have investigated the optimization of these methods for controlled/living radical polymerization (CLRP), which faces issues with oxygen intolerance. This research has led to the development of oxygen-tolerant CLRP, including with the use of enzyme degassing of RAFT (Enz-RAFT), atom-transfer radical (ATRP) that possesses tolerance to air, and photoinduced electron/energy transfer–RAFT (PET–RAFT) polymerization. Through the use of liquid-handling robots, Tamasi et al. demonstrated the use of automated synthesis with executing multi-step procedures, enabling the reactions to investigate more elaborate schemes, such as with scale and complexity. Lee Cronin and his team have developed a modular synthesis machine called the chemputer which uses a dedicated programming language for chemical synthesis.

Sources: en.wikipedia.org

Frequently asked questions

How does thymosin alpha 1 differ from thymosin fraction 5?

Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.

Which gene encodes the precursor protein?

The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.

Is the peptide found naturally in the human body?

It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.

胸腺素α1是激素吗?

它不是经典的内分泌激素,而是一种免疫调节肽。其作用主要通过局部免疫细胞间的信号传递实现,而非经血液循环作用于远隔器官。

Network